BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $15.00 Price Target at Bank of America

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its target price hoisted by analysts at Bank of America from $13.00 to $15.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. Bank of America's price objective would suggest a potential upside of 66.30% from the company's current price.

BCRX has been the subject of several other research reports. Wall Street Zen cut BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Needham & Company LLC reiterated a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, June 25th. Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded up $0.02 during trading hours on Tuesday, reaching $9.02. 3,551,652 shares of the company's stock were exchanged, compared to its average volume of 3,032,394. The company's 50 day moving average is $10.03 and its two-hundred day moving average is $8.58. The company has a market cap of $1.89 billion, a P/E ratio of -34.69, a price-to-earnings-growth ratio of 2.68 and a beta of 1.04. BioCryst Pharmaceuticals has a 1 year low of $6.02 and a 1 year high of $11.31.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC grew its position in shares of BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the last quarter. Vanguard Group Inc. lifted its stake in BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after buying an additional 1,583,826 shares in the last quarter. Eversept Partners LP lifted its stake in BioCryst Pharmaceuticals by 269.9% in the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after buying an additional 1,444,907 shares in the last quarter. Nuveen LLC acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $10,677,000. Finally, Jupiter Asset Management Ltd. increased its position in BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after buying an additional 971,040 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.